Fibrates
Mostrando 1-12 de 23 artigos, teses e dissertações.
-
1. Familial Chylomicronemia Syndrome-Induced Acute Necrotizing Pancreatitis during Pregnancy
Abstract Acute pancreatitis is a rare condition in pregnancy, associated with a high mortality rate. Hypertriglyceridemia represents its second most common cause.We present the case of a 38-year-old woman in the 24th week of gestation with a history of hypertriglyceridemia and recurrent episodes of pancreatitis. She was admitted to our hospital with acute pa
Rev. Bras. Ginecol. Obstet.. Publicado em: 2021-03
-
2. Chemical degradation kinetics of fibrates: bezafibrate, ciprofibrate and fenofibrate
ABSTRACT Fibrates are drugs used for the treatment of hypertriglyceridemia and for the prevention of atherosclerosis. Three drugs in the fibrate class, ciprofibrate, fenofibrate and bezafibrate, were chosen for this study because their raw materials are readily available and because scientific publications on these compounds is limited. To evaluate their int
Braz. J. Pharm. Sci.. Publicado em: 2016-09
-
3. Determinação voltamétrica de fibratos em formulações farmacêuticas utilizando eletrodos de carbono vítreo modificados com nanotubos de carbono / Voltammetric determination of fibrates in pharmaceutical formulations using glassy carbon electrode modified with carbon nanotubes
Neste trabalho foram desenvolvidos métodos voltamétricos para a determinação de genfibrozila (GEN) e bezafibrato (BZF) em formulações farmacêuticas, empregando eletrodos de carbono vítreo modificados com filme de dihexadecil hidrogênio fosfato contendo nanotubos de carbono de paredes múltiplas tratados quimicamente. Inicialmente estudou-se o compor
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 27/07/2012
-
4. Agonistas PPAR (Rosiglitazona, Bezafibrato e Fenofibrato) e alterações bioquímicas e estruturais em órgãos-alvo de camundongos C57BL/6 alimentados com dieta hiperlipídica rica em sacarose / PPAR agonists (Rosiglitazone, Bezafibrate and Fenofibrate) and biochemical and structural changes in target organs of C57BL/6 mice fed a high-fat high-sucrose diet
This work aimed to evaluate the effect of peroxisome proliferator-activated receptor (PPAR) agonists (rosiglitazone, fenofibrate and bezafibrate) on lipid and glucose metabolism, body mass, and adipose and pancreatic tissue morphology in a model of diet-induced type 2 diabetes and overweight in mice. Two-month-old male C57BL/6 mice were fed a standard chow (
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 07/06/2010
-
5. Dyslipidemia in HIV-infected individuals
Metabolic complications continue to play a major role in the management of HIV infection. Dyslipidemia associated with HIV infection and with the use of combined antiretroviral therapy includes elevations in triglycerides, reduced high-density cholesterol, and variable increases in low-density and total cholesterol. The association between dyslipidemia and s
Brazilian Journal of Infectious Diseases. Publicado em: 2010-12
-
6. Efeito de acidos graxos n-3 e n-6 sobre a expressão e atividade da proteina de transferencia de colesteril ester (CETP) em camundongos transgenicos / Effects of n-3 and n-6 fatty acids on the cholesteryl ester transfer protein (CETP) expression and activity in transgenic mice
Os óleos de peixe e de milho são fontes de ácidos graxos poli-insaturados (PUFA) n-3 e n-6, respectivamente. Estes ácidos graxos são ligantes naturais dos receptores ativados por proliferadores de peroxissomos (PPARs) e, dessa forma, modificam a expressão de diversos genes envolvidos no metabolismo de lipídios. A proteína de transferência de coleste
Publicado em: 2008
-
7. Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy
The use of highly active antiretroviral therapy (HAART) in HIV-infected patients has been associated with the development of risk factors for cardiovascular diseases (CD) including dyslipidemia and insulin resistance, hypertriglyceridemia being the most frequent metabolic disturbance in these patients. Fibrates are indicated when hypertriglyceridemia is acce
Brazilian Journal of Infectious Diseases. Publicado em: 2006-06
-
8. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.
Epidemiological and transgenic animal studies have implicated apo C-III as a major determinant of plasma triglyceride metabolism. Since fibrates are very efficient in lowering triglycerides, it was investigated whether fibrates regulate apo C-III gene expression. Different fibrates lowered rat liver apo C-III mRNA levels up to 90% in a dose- and time-depende
-
9. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, which rationale, metho
BioMed Central.
-
10. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
In view of the evidence linking plasma high density lipoprotein (HDL)-cholesterol levels to a protective effect against coronary artery disease and the widespread use of fibrates in the treatment of hyperlipidemia, the goal of this study was to analyze the influence of fibrates on the expression of apolipoprotein (apo) A-II, a major protein constituent of HD
-
11. Anti-atherogenic effects of fibrates in type 2 diabetes
Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic dyslipidaemia with either fibrates or statins reduces the risk of future coronary events in such patients. However, until recently no reported study had be
BioMed Central.
-
12. The inhibition of the human cholesterol 7α-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor α and peroxisome proliferator-activated receptor α heterodimer
In previous work, we showed that the binding of the liver x receptor α:peroxisome proliferator-activated receptor α (LXRα:PPARα) heterodimer to the murine Cyp7a1 gene promoter antagonizes the stimulatory effect of their respective ligands. In this study, we determined if LXRα:PPARα can also regulate human CYP7A1 gene promoter activity. Co-expression of
Oxford University Press.